Suven Pharmaceuticals (BOM:543064) LT-Debt-to-Total-Asset : 0.01 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Suven Pharmaceuticals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Suven Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.01.

Suven Pharmaceuticals's long-term debt to total assets ratio increased from Mar. 2023 (0.00) to Mar. 2024 (0.01). It may suggest that Suven Pharmaceuticals is progressively becoming more dependent on debt to grow their business.

Suven Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

The historical data trend for Suven Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suven Pharmaceuticals LT-Debt-to-Total-Asset Chart

Suven Pharmaceuticals Annual Data

Trend

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.08

0.03

0.02

0.01

Suven Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	0.01

Suven Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Suven Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (A: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2024 )	/	Total Assets (A: Mar. 2024 )
	=	212.356	/	22540.865
	=	0.01

Suven Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	212.356	/	22540.865
	=	0.01

Suven Pharmaceuticals (BOM:543064) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Suven Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Suven Pharmaceuticals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Suven Pharmaceuticals (BOM:543064) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Suven Pharmaceuticals Ltd (BOM:543064) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

SUVENPHAR:India

Address

3rd Floor, Road No. 5, Avenue 7, Banjara Hills, No. 8-2-334, SDE Serene Chambers, Hyderabad, TG, IND, 500034

Website

https://www.suvenpharm.com

Suven Pharmaceuticals Ltd is engaged in the development and manufacturing of Intermediates, Active Pharmaceutical Ingredients (API), specialty chemicals and formulated drugs under Contract Research and Manufacturing Services (CRAMS) for global pharmaceutical, biotechnology and chemical companies. The company has single operating segment that is Pharmaceuticals Manufacturing & Services and its geographical segments include India; the USA; Europe and the Rest of the World. The company derives a majority of revenue from the Europe segment.

Suven Pharmaceuticals (BOM:543064) Headlines

No Headlines